Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first-line matter?

被引：0
|
作者：
Bittoni, Alessandro
Scartozzi, Mario
Pistelli, Mirco
Galizia, Eva
Del Prete, Michela
Giampieri, Riccardo
Faloppi, Luca
Bianconi, Maristella
Maccaroni, Elena
Cascinu, Stefano
机构：
[1] Univ Politecn Marche, Scuola Specializzaz Oncol Med, Ancona, Italy
[2] Univ Politecn Marche, AO Osped Riuniti, Clin Oncol Med, Ancona, Italy
[3] Univ Politecn Marche, Scuola Specializzaz Oncol, Ancona, Italy
[4] Osped Profili, Fabriano, Italy
[5] Univ Politecn Marche, AO Osped Riuniti, Ancona, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14663
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Intensive up-front treatment versus a sequential approach in advanced gastric cancer patients: Does first line matter?
    Bittoni, Alessandro
    Scartozzi, Mario
    Pistelli, Mirco
    Galizia, Eva
    Del Prete, Michela
    Giampieri, Riccardo
    Faloppi, Luca
    Bianconi, Maristella
    Maccaroni, Elena
    Cascinu, Stefano
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [2] Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment
    Gurler, Fatih
    Ilhan, Aysegul
    Guven, Deniz Can
    Turhan, Okan
    Inci, Bediz Kurt
    Sutcuoglu, Osman
    Yildiz, Fatih
    Arik, Zafer
    Oksuzoglu, Berna
    Yalcin, Suayib
    Ozdemir, Nuriye
    Yazici, Ozan
    Ozet, Ahmet
    ANTI-CANCER DRUGS, 2022, 33 (01) : E477 - E485
  • [3] First-line drug selection versus sequential treatment in advanced pancreatic cancer: Does it really matter? Multi-institutional Canadian perspective
    Barrera, Ivan
    Papneja, Neha
    Ranger, Jill
    Papneja, Abhishek
    Novotny, Petr
    Ahmed, Shahid
    Batist, Gerald
    Kavan, Petr
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [4] Pembrolizumab as a first-line treatment for advanced gastric cancer
    Chau, Ian
    LANCET ONCOLOGY, 2023, 24 (11): : 1158 - 1159
  • [5] Up-front versus sequential randomizations for inference on adaptive treatment strategies
    Ko, Jin H.
    Wahed, Abdus S.
    STATISTICS IN MEDICINE, 2012, 31 (09) : 812 - 830
  • [6] Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer
    Kruijtzer, CMF
    Boot, H
    Beijnen, JH
    Lochs, HL
    Parnis, FX
    Planting, AST
    Pelgrims, JMG
    Williams, R
    Mathôt, RAA
    Rosing, H
    Schot, ME
    van Tinteren, H
    Schellens, JHM
    ANNALS OF ONCOLOGY, 2003, 14 (02) : 197 - 204
  • [7] Heterogeneity in the first-line treatment of patients with advanced or metastatic gastric cancer in the US
    Abrams, T.
    Hess, L.
    Zhu, Y.
    Schelman, W.
    Liepa, A.
    Fuchs, C.
    ANNALS OF ONCOLOGY, 2016, 27 : 115 - 115
  • [8] HIPEC as Up-Front Treatment in Locally Advanced Ovarian Cancer
    Karanikas, Michail
    Kofina, Konstantinia
    Kyziridis, Dimitrios
    Trypsianis, Grigorios
    Kalakonas, Apostolos
    Tentes, Antonios-Apostolos
    CANCERS, 2024, 16 (20)
  • [9] Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
    Lan, Yan-qin
    Kong, Ling-jun
    Lin, Xiao-yan
    Xu, Qian
    Gao, Xin-yan
    Wu, Ri-ping
    Wang, Xin-li
    Zhong, Dong-ta
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (06) : 1007 - 1015
  • [10] Phase II Trial of XELOX as First-Line Treatment for Patients with Advanced Gastric Cancer
    Luo, Hui-yan
    Xu, Rui-hua
    Wang, Feng
    Qiu, Miao-zhen
    Li, Yu-hong
    Li, Fang-hua
    Zhou, Zhi-wei
    Chen, Xiao-qin
    CHEMOTHERAPY, 2010, 56 (02) : 94 - 100
12345